Selinexor plus COPL for newly diagnosed advanced NK/T lymphoma
Part of Cancer clinical trials.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 14 or older, and can be any sex
- Your NK/T-cell lymphoma has been newly diagnosed and confirmed by biopsy/pathology
- Your disease must have at least one measurable tumor spot (size rules)
- Your performance status is ECOG 0 to 2, meaning you’re able to do daily activities (with limited assistance for 1–2)
- You have advanced stage III to IV lymphoma, with an expected survival of more than 6 months
- Your blood, liver, and kidney tests are within required ranges (and fibrinogen is normal at the start of cycle 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, selinexor and azacitidine, given after a stem cell transplant to help prevent the lymphoma from coming back. The goal is to see if this combination is safe and effective as a maintenance treatment.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This trial tests a combination of three drugs (selinexor, an anti-PD-1 antibody, and golidocitinib) for patients with relapsed or refractory NKTCL. The goal is to see if this combination can effectively treat the lymphoma and improve outcomes.
This trial is testing a combination of three treatments for a rare type of lymphoma called NKTCL that has come back or not responded to prior therapy. The treatments include a pill (selinexor), an immune-boosting drug (anti-PD-1 antibody), and a chemotherapy combination (P-GemOx). The goal is to see if this combination can help control the lymphoma and improve outcomes.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.